Arovella Therapeutics Says FDA Accepts Investigational New Drug Application for Blood Cancer Drug Candidate

MT Newswires Live

01/29

Arovella Therapeutics (ASX:ALA) said the US Food and Drug Administration (FDA) accepted its investigational new drug application for its ALA-101 drug candidate to commence first-in-human clinical trials in patients with CD19-positive non-Hodgkin's lymphoma and leukaemia, according to a Thursday Australian bourse filing.

This will allow it to conduct its phase one trial in Australia via the clinical trial notification scheme rather than the "lengthier" clinical trial application pathway, per the filing. The planned study will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of the candidate in patients with relapsed/refractory CD19-positive non-Hodgkin's lymphoma and leukaemia.

Its shares rose 2% in recent trading on Thursday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2607977190"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2607977190\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2607977190?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-29 12:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607977190","market":"sg","top_or_hot":-1,"title":"Arovella Therapeutics Says FDA Accepts Investigational New Drug Application for Blood Cancer Drug Candidate","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ARVEF\">Arovella Therapeutics</a> (ASX:ALA) said the US Food and Drug Administration (FDA) accepted its investigational new drug application for its ALA-101 drug candidate to commence first-in-human clinical trials in patients with CD19-positive non-Hodgkin's lymphoma and leukaemia, according to a Thursday Australian bourse filing.</p><p>This will allow it to conduct its phase one trial in Australia via the clinical trial notification scheme rather than the \"lengthier\" clinical trial application pathway, per the filing. The planned study will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of the candidate in patients with relapsed/refractory CD19-positive non-Hodgkin's lymphoma and leukaemia.</p><p>Its shares rose 2% in recent trading on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arovella Therapeutics Says FDA Accepts Investigational New Drug Application for Blood Cancer Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArovella Therapeutics Says FDA Accepts Investigational New Drug Application for Blood Cancer Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-29 12:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ARVEF\">Arovella Therapeutics</a> (ASX:ALA) said the US Food and Drug Administration (FDA) accepted its investigational new drug application for its ALA-101 drug candidate to commence first-in-human clinical trials in patients with CD19-positive non-Hodgkin's lymphoma and leukaemia, according to a Thursday Australian bourse filing.</p><p>This will allow it to conduct its phase one trial in Australia via the clinical trial notification scheme rather than the \"lengthier\" clinical trial application pathway, per the filing. The planned study will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of the candidate in patients with relapsed/refractory CD19-positive non-Hodgkin's lymphoma and leukaemia.</p><p>Its shares rose 2% in recent trading on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2607977190","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607977190","pubTimestamp":1769660439,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Arovella Therapeutics (ASX:ALA) said the US Food and Drug Administration (FDA) accepted its investigational new drug application for its ALA-101 drug candidate to commence first-in-human clinical tria","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ALA.AU":"AROVELLA THERAPEUTICS LTD","LENZ":"Therapeutics","BK7096":"制药","BK4007":"制药","BK4539":"次新股"},"translate_title":"Arovella Therapeutics表示FDA接受血癌候选药物的研究性新药申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"ALA.AU":1},"content_text":"Arovella Therapeutics (ASX:ALA) said the US Food and Drug Administration (FDA) accepted its investigational new drug application for its ALA-101 drug candidate to commence first-in-human clinical trials in patients with CD19-positive non-Hodgkin's lymphoma and leukaemia, according to a Thursday Australian bourse filing.This will allow it to conduct its phase one trial in Australia via the clinical trial notification scheme rather than the \"lengthier\" clinical trial application pathway, per the filing. The planned study will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of the candidate in patients with relapsed/refractory CD19-positive non-Hodgkin's lymphoma and leukaemia.Its shares rose 2% in recent trading on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}